Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR25617870

— · C

3f4f1db9-e0a3-5d18-bb3d-607d8e7389dc

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.330
  • INTERFERON_ALPHA_RESPONSE+0.320
  • INTERFERON_GAMMA_RESPONSE+0.230
  • MITOTIC_SPINDLE+0.230
  • OXIDATIVE_PHOSPHORYLATION+0.210
  • IL6_JAK_STAT3_SIGNALING+0.180
  • PI3K_AKT_MTOR_SIGNALING+0.180
  • TGF_BETA_SIGNALING+0.160
  • NOTCH_SIGNALING+0.150
  • ALLOGRAFT_REJECTION+0.120

Top 10 suppressed

  • APICAL_SURFACE-0.420
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
  • ESTROGEN_RESPONSE_EARLY-0.380
  • CHOLESTEROL_HOMEOSTASIS-0.360
  • KRAS_SIGNALING_DN-0.330
  • MYOGENESIS-0.310
  • ANGIOGENESIS-0.300
  • HYPOXIA-0.290
  • MYC_TARGETS_V2-0.290
  • UV_RESPONSE_UP-0.290

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG833
mng-umap@100
——0.775
2MNG724
mng-umap@100
——0.772
3TCGA-AC-A23C-01A-12R-A169-07
breast-umap@18
—A0.771
4ERR4976616
breast-umap@18
—C0.770
5R337
bladder-landscape@3
——0.761
6MNG876
mng-umap@100
——0.757
7SJEPD032426_D1.RNA-Seq
medullo-epn-umap@date-based
EPNAnaplastic EPN0.749
888302
medullo-epn-umap@date-based
EPNSupratentorial EPN0.747
9MDT-AP-3097
medullo-epn-umap@date-based
MedMedulloblastoma0.744
10MNG642
mng-umap@100
——0.744

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.330Remibrutinib— uncovered
INTERFERON_ALPHA_RESPONSE0.320Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.230Idelalisib— uncovered
MITOTIC_SPINDLE0.230Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.210Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.180Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.180Inavolisib— uncovered
TGF_BETA_SIGNALING0.160Inavolisib— uncovered
NOTCH_SIGNALING0.150Inavolisib— uncovered
ALLOGRAFT_REJECTION0.120Idelalisib— uncovered
G2M_CHECKPOINT0.100Inavolisib— uncovered
HEME_METABOLISM0.100Temsirolimus— uncovered
ANDROGEN_RESPONSE0.080Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.060Idelalisib— uncovered
FATTY_ACID_METABOLISM0.050Inavolisib— uncovered
KRAS_SIGNALING_UP0.040Inavolisib— uncovered
DNA_REPAIR0.030Idelalisib— uncovered
MYC_TARGETS_V10.030Inavolisib— uncovered
ADIPOGENESIS0.020Inavolisib— uncovered
UV_RESPONSE_DN0.010Inavolisib— uncovered